The massive GAAP EPS miss and weak organic growth (2.4% vs 8.0-9.5% guidance) create significant credibility risk. The maintained guidance implies a dramatic acceleration in the remaining three quarters, watch for pre-announcements or guidance cuts. The cyber incident impact and Spinal Implants collapse warrant deeper investigation. Expect negative price reaction at open.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $293.78entry
- T+1 · 7mo ago −0.97%α −0.62% · $290.94
- T+5 · 6mo ago −2.83%α −5.18% · $285.47
- T+20 · 6mo ago +1.86%α −3.41% · $299.24
- T+60 · 4mo ago +14.62%α +12.07% · $336.74
Price Chart
How similar events traded
Executive Summary
Stryker reported Q1 2026 GAAP EPS of $1.93 (vs consensus $2.98, a 35.2% miss) and adjusted EPS of $2.60 (down 8.5% YoY). Revenue of $6.02B missed the $6.33B consensus by 4.9%, with organic sales growth of only 2.4%, well below the 8.0-9.5% full-year guidance. The company maintained its full-year guidance despite the weak quarter, citing a quick recovery from a cyber incident, but the headline numbers represent a significant miss on both top and bottom lines.
Key Financial Metrics
Key Facts
- Reported GAAP EPS of $1.93 missed consensus of $2.98 by 35.2%
- Adjusted EPS of $2.60 declined 8.5% YoY
- Revenue of $6.02B missed consensus of $6.33B by 4.9%
- Organic net sales growth of only 2.4% vs full-year guidance of 8.0-9.5%
- Adjusted operating margin contracted 180 bps to 21.1%
- Full-year 2026 guidance maintained: organic sales growth 8.0-9.5%, adjusted EPS $14.90-$15.10
- Spinal Implants revenue collapsed 98.9% YoY to $2M (likely due to Inari acquisition restructuring)
- Vascular segment grew 27.5% reported, but Medical segment declined 4.6%
Financial Impact
EPS miss of $1.05 vs consensus on GAAP basis; revenue miss of ~$310M; adjusted EPS down 8.5% YoY
Risk Factors
- Full-year guidance appears unrealistic given Q1 organic growth of 2.4% vs 8.0-9.5% target
- Cyber incident may have lingering operational impacts beyond Q1
- Spinal Implants business effectively zeroed out, restructuring risk
- Adjusted operating margin compression of 180 bps signals cost headwinds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285455 |
Track record
29 reports on SYK
5 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +23.40% at T+20 after the Oct 7, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 12, 20266d ago Court Ruling Neutral 3/10 Entry $309.64 Now $310.72 +0.35% settles Dec 14
- Nov 9, 20268d ago 8-K Neutral 2/10 Entry $324.29 Now $310.72 −4.18% settles Dec 9
- Nov 5, 202612d ago 144 Neutral 3/10 Entry $325.87 Now $310.72 −4.65% settles Dec 7
- Nov 4, 202613d ago S-3ASR Neutral 3/10 Entry $335.08 Now $310.72 −7.27% settles Dec 4
- Nov 3, 202614d ago Institutional Cluster Mixed 3/10 Entry $310.55 Now $310.72 +0.05% settles Dec 2
- Oct 29, 202619d ago 8-K Bearish 6/10 No price data
- Oct 29, 202619d ago Press Release Bearish 6/10 Entry $291.86 Now $310.72 −6.46% settles Nov 30
- Oct 26, 202622d ago Press Release Neutral 4/10 Entry $306.13 Now $310.72 +1.50% settles Nov 23
- Oct 20, 202629d ago PTAB Trial Bearish 5/10 Entry $297.60 Now $310.72 −4.41% settles Nov 18
- Oct 7, 20265w ago ANALYST-UPGRADE Bullish 4/10 Entry $275.25 to $339.65 Now $310.72 +12.89% ▲ +23.40% +24.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers